BioLight Life Sciences Ltd (BOLT) — Cash Flow-to-Debt Ratio
BioLight Life Sciences Ltd (BOLT) has a Cash Flow-to-Debt Ratio of -2.45x as of December 2025, meaning its operating cash flow of ILA-5.49 Million could theoretically repay -2% of its total liabilities (ILA2.24 Million) in one year. See BioLight Life Sciences Ltd (BOLT) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioLight Life Sciences Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BioLight Life Sciences Ltd across 14 annual periods. Also explore BioLight Life Sciences Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioLight Life Sciences Ltd (2012–2025)
Year-by-year debt coverage analysis for BioLight Life Sciences Ltd. For market capitalisation and broader financial context, see BOLT market cap.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.84x | ILA-10.85 Million | ILA2.24 Million | ▼ -48.8% |
| 2024 | -3.25x | ILA-10.99 Million | ILA3.38 Million | ▼ -7.0% |
| 2023 | -3.04x | ILA-9.58 Million | ILA3.15 Million | ▼ -5.7% |
| 2022 | -2.87x | ILA-9.54 Million | ILA3.32 Million | ▲ +21.0% |
| 2021 | -3.64x | ILA-10.03 Million | ILA2.75 Million | ▼ -50.9% |
| 2020 | -2.41x | ILA-11.39 Million | ILA4.72 Million | ▼ -6.9% |
| 2019 | -2.26x | ILA-15.36 Million | ILA6.80 Million | ▼ -25.9% |
| 2018 | -1.79x | ILA-22.39 Million | ILA12.49 Million | ▼ -18.5% |
| 2017 | -1.51x | ILA-25.32 Million | ILA16.73 Million | ▼ -6.2% |
| 2016 | -1.43x | ILA-26.94 Million | ILA18.90 Million | ▲ +3.9% |
| 2015 | -1.48x | ILA-24.04 Million | ILA16.21 Million | ▲ +19.3% |
| 2014 | -1.84x | ILA-26.99 Million | ILA14.70 Million | ▲ +14.4% |
| 2013 | -2.15x | ILA-26.23 Million | ILA12.22 Million | ▲ +49.8% |
| 2012 | -4.27x | ILA-19.46 Million | ILA4.55 Million | — |